Kimball Electronics, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025 (First Quarter of Fiscal Year 2026). Kimball Electronics, Inc. is a global provider of electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions serving automotive, medical, and industrial markets. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Sales | $365.6 million | $374.3 million |
| Gross Profit | $28.8 million (7.9% margin) | $23.6 million (6.3% margin) |
| Operating Income | $14.5 million (4.0% margin) | $9.1 million (2.4% margin) |
| Net Income | $10.1 million | $3.2 million |
| Diluted EPS | $0.40 | $0.12 |
| Cash from Operations | $8.1 million | $45.5 million |
| Total Debt (Outstanding) | $137.9 million | $147.5 million |
| Cash & Equivalents | $75.7 million | $78.4 million |
| Working Capital | $378.5 million | $381.0 million |
Material Changes vs. Prior Period
- Revenue Mix: Consolidated net sales decreased 2% year-over-year. The decline was driven by a 10% drop in the Automotive vertical (loss of a major program) and a 3% decline in Industrial. Conversely, the Medical vertical grew 13% due to increased sales with the largest medical customer.
- Profitability: Operating income increased 59% and Net Income increased 220%. This improvement was primarily due to cost structure alignment (restructuring), efficiencies from the Tampa facility closure, and a $2.0 million recovery from a terminated customer program recorded in selling and administrative expenses.
- Restructuring: The company recorded $1.4 million in restructuring expenses, primarily related to the Tampa Closure Plan and workforce resizing. The Tampa closure is considered substantially complete.
- Tax Impact: The effective tax rate was 8.3% (vs. a benefit in the prior year), driven by a partial release of a valuation allowance following the enactment of the "One Big Beautiful Bill Act" (2025 U.S. tax reform).
- Divestiture: The company sold 100% of its equity in GES in the prior year; no sales from this unit were recorded in the current quarter.
Guidance, Outlook, and Risks
- Liquidity: The company maintains a strong liquidity position with $370.0 million in available short-term liquidity (cash plus unused credit facilities). Management expects to meet working capital needs for at least the next 12 months.
- Capital Expenditures: Commitments are approximately $29.0 million, focused on a new medical facility in Indianapolis and new program wins.
- Outlook: Management expects to recover tariff costs by passing them to customers but notes that failure to do so could adversely impact results. Open orders were flat at $593 million.
- Risks: Key risks include global economic conditions, geopolitical conflicts, supply chain disruptions, and the impact of tariffs. The company continues to monitor the need for additional restructuring due to end-market demand pressures.
Investor Verification Checklist
- Automotive Exposure: Verify the long-term impact of the lost major automotive program on future revenue stability.
- Tampa Asset Sale: Confirm the timeline and expected proceeds from the sale of the Tampa facility land and building (currently held for sale at $6.6 million).
- Tax Reform Impact: Assess the full-year implications of the 2025 U.S. tax reform on deferred tax assets and future effective tax rates.
- Medical Growth Sustainability: Evaluate the concentration risk associated with the 13% growth driven by the largest medical customer.
- Working Capital Efficiency: Monitor Cash Conversion Days (83 days in Q1 2026) to ensure continued improvement in working capital management.